| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Microbiology | 1 | 2018 | 134 | 0.63 | Why? |
| Societies, Scientific | 1 | 2018 | 414 | 0.57 | Why? |
| Publications | 1 | 2020 | 463 | 0.56 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 1115 | 0.43 | Why? |
| Chromosomes, Human, Pair 3 | 2 | 2021 | 195 | 0.37 | Why? |
| Bacteria | 1 | 2019 | 1897 | 0.35 | Why? |
| Communicable Diseases | 2 | 2019 | 2148 | 0.33 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.30 | Why? |
| ABO Blood-Group System | 3 | 2021 | 995 | 0.25 | Why? |
| Multigene Family | 2 | 2021 | 377 | 0.25 | Why? |
| Hepatitis C, Chronic | 3 | 2017 | 973 | 0.23 | Why? |
| HIV Infections | 6 | 2018 | 11620 | 0.22 | Why? |
| Simeprevir | 2 | 2017 | 62 | 0.21 | Why? |
| Cross Infection | 3 | 2021 | 8675 | 0.20 | Why? |
| Toxoplasmosis, Congenital | 1 | 2018 | 10 | 0.19 | Why? |
| Computer Terminals | 1 | 2018 | 18 | 0.19 | Why? |
| Toxoplasma | 1 | 2018 | 61 | 0.19 | Why? |
| Toxoplasmosis | 1 | 2019 | 59 | 0.19 | Why? |
| Platelet-Derived Growth Factor | 1 | 2017 | 21 | 0.18 | Why? |
| Antibodies, Protozoan | 1 | 2018 | 121 | 0.18 | Why? |
| Blood Group Incompatibility | 1 | 2017 | 44 | 0.18 | Why? |
| Vibration | 1 | 2018 | 68 | 0.18 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.17 | Why? |
| Abdominal Cavity | 1 | 2017 | 22 | 0.17 | Why? |
| Analgesia, Patient-Controlled | 1 | 2017 | 20 | 0.17 | Why? |
| Italy | 17 | 2021 | 38444 | 0.17 | Why? |
| Neuromuscular Diseases | 1 | 2021 | 303 | 0.17 | Why? |
| Rubella | 1 | 2019 | 127 | 0.17 | Why? |
| Rifamycins | 1 | 2017 | 20 | 0.17 | Why? |
| Blood Chemical Analysis | 1 | 2021 | 541 | 0.17 | Why? |
| Bronchiolitis Obliterans | 1 | 2017 | 86 | 0.17 | Why? |
| Phlebotomy | 1 | 2018 | 131 | 0.17 | Why? |
| Clinical Medicine | 1 | 2018 | 93 | 0.17 | Why? |
| Energy Metabolism | 1 | 2021 | 451 | 0.16 | Why? |
| Anesthesia | 2 | 2018 | 1236 | 0.16 | Why? |
| HIV Integrase Inhibitors | 1 | 2018 | 173 | 0.16 | Why? |
| Morphine | 1 | 2017 | 71 | 0.16 | Why? |
| Metabolome | 1 | 2021 | 624 | 0.16 | Why? |
| Range of Motion, Articular | 1 | 2017 | 168 | 0.16 | Why? |
| Intraabdominal Infections | 1 | 2017 | 90 | 0.16 | Why? |
| Pregnancy Trimester, First | 1 | 2018 | 366 | 0.16 | Why? |
| Dry Eye Syndromes | 1 | 2018 | 113 | 0.16 | Why? |
| Transplants | 1 | 2017 | 136 | 0.16 | Why? |
| Computer Security | 1 | 2020 | 408 | 0.16 | Why? |
| Bone Diseases | 1 | 2017 | 101 | 0.15 | Why? |
| Hyaluronic Acid | 1 | 2017 | 168 | 0.15 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.15 | Why? |
| Transplantation Conditioning | 1 | 2017 | 323 | 0.15 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.15 | Why? |
| Transfusion Reaction | 1 | 2017 | 245 | 0.15 | Why? |
| Anti-Infective Agents | 2 | 2017 | 1766 | 0.15 | Why? |
| Thrombelastography | 1 | 2021 | 627 | 0.15 | Why? |
| Catheterization, Peripheral | 1 | 2018 | 249 | 0.14 | Why? |
| Editorial Policies | 1 | 2020 | 408 | 0.14 | Why? |
| Osteoarthritis, Knee | 1 | 2017 | 158 | 0.14 | Why? |
| Invasive Fungal Infections | 1 | 2019 | 274 | 0.14 | Why? |
| Abdomen | 1 | 2018 | 424 | 0.14 | Why? |
| Critical Illness | 5 | 2021 | 17281 | 0.14 | Why? |
| Privacy | 1 | 2020 | 636 | 0.14 | Why? |
| Graft Rejection | 2 | 2017 | 1766 | 0.14 | Why? |
| Complement Activation | 1 | 2021 | 949 | 0.13 | Why? |
| Antibody Affinity | 1 | 2018 | 1078 | 0.13 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.13 | Why? |
| Pain, Postoperative | 1 | 2017 | 289 | 0.12 | Why? |
| Semen | 1 | 2018 | 550 | 0.12 | Why? |
| Klebsiella Infections | 1 | 2018 | 466 | 0.12 | Why? |
| HIV-1 | 2 | 2018 | 3365 | 0.12 | Why? |
| Cytomegalovirus Infections | 1 | 2019 | 667 | 0.12 | Why? |
| Radiology, Interventional | 1 | 2017 | 398 | 0.12 | Why? |
| Klebsiella pneumoniae | 1 | 2018 | 658 | 0.11 | Why? |
| Erythrocytes | 1 | 2017 | 617 | 0.11 | Why? |
| Intracranial Aneurysm | 1 | 2017 | 504 | 0.11 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.11 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.11 | Why? |
| Observational Studies as Topic | 1 | 2019 | 1887 | 0.11 | Why? |
| Genotype | 2 | 2021 | 4697 | 0.11 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.11 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2017 | 698 | 0.11 | Why? |
| Coronary Artery Bypass | 1 | 2017 | 629 | 0.11 | Why? |
| Circadian Rhythm | 1 | 2017 | 607 | 0.11 | Why? |
| Hepacivirus | 2 | 2017 | 1509 | 0.11 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2021 | 3607 | 0.10 | Why? |
| Pain | 1 | 2018 | 1084 | 0.10 | Why? |
| Robotic Surgical Procedures | 1 | 2018 | 787 | 0.10 | Why? |
| Biomedical Research | 2 | 2020 | 5270 | 0.10 | Why? |
| Monitoring, Physiologic | 1 | 2021 | 1956 | 0.10 | Why? |
| Pain Management | 1 | 2018 | 854 | 0.10 | Why? |
| Graft Survival | 1 | 2012 | 587 | 0.09 | Why? |
| Antimicrobial Stewardship | 1 | 2017 | 931 | 0.09 | Why? |
| Respiratory Insufficiency | 2 | 2020 | 7301 | 0.09 | Why? |
| Sex Characteristics | 1 | 2017 | 1120 | 0.09 | Why? |
| Genetic Predisposition to Disease | 2 | 2021 | 4027 | 0.09 | Why? |
| Preoperative Care | 1 | 2018 | 1515 | 0.09 | Why? |
| Liver Cirrhosis | 2 | 2017 | 1810 | 0.09 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.09 | Why? |
| Logistic Models | 2 | 2020 | 9089 | 0.09 | Why? |
| Shock, Septic | 1 | 2017 | 1313 | 0.08 | Why? |
| Humans | 43 | 2021 | 930598 | 0.08 | Why? |
| Male | 28 | 2021 | 367725 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2021 | 2955 | 0.08 | Why? |
| Endovascular Procedures | 1 | 2017 | 1302 | 0.08 | Why? |
| Analgesics, Opioid | 1 | 2017 | 1070 | 0.08 | Why? |
| Periodicals as Topic | 1 | 2020 | 1492 | 0.08 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.08 | Why? |
| Aged | 19 | 2021 | 215776 | 0.08 | Why? |
| Female | 27 | 2021 | 380317 | 0.08 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Lung Transplantation | 1 | 2017 | 1554 | 0.07 | Why? |
| Neurosurgical Procedures | 1 | 2017 | 1738 | 0.07 | Why? |
| Sustained Virologic Response | 2 | 2017 | 378 | 0.07 | Why? |
| Liver Diseases | 1 | 2020 | 2698 | 0.07 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.07 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.07 | Why? |
| Immunoglobulin G | 2 | 2019 | 21571 | 0.07 | Why? |
| Pain Measurement | 2 | 2018 | 533 | 0.07 | Why? |
| Sepsis | 2 | 2021 | 3517 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.06 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.06 | Why? |
| Immunoassay | 1 | 2019 | 4485 | 0.06 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.06 | Why? |
| Adult | 16 | 2021 | 244371 | 0.06 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.06 | Why? |
| Quality of Life | 2 | 2021 | 9820 | 0.06 | Why? |
| Occupational Diseases | 1 | 2018 | 2787 | 0.06 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.06 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.06 | Why? |
| Infant, Newborn | 3 | 2018 | 23105 | 0.06 | Why? |
| Europe | 1 | 2018 | 12702 | 0.06 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2019 | 9091 | 0.06 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.06 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.05 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.05 | Why? |
| Adolescent | 7 | 2020 | 86841 | 0.05 | Why? |
| Percutaneous Coronary Intervention | 1 | 2017 | 3646 | 0.05 | Why? |
| Chromosomes, Human, Pair 9 | 1 | 2020 | 196 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.05 | Why? |
| Blood Grouping and Crossmatching | 1 | 2020 | 125 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.05 | Why? |
| Ribavirin | 2 | 2017 | 1182 | 0.05 | Why? |
| Complement C5a | 1 | 2021 | 116 | 0.05 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.05 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 13 | 0.05 | Why? |
| Punctures | 1 | 2018 | 89 | 0.04 | Why? |
| Photopheresis | 1 | 2017 | 33 | 0.04 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Infant | 2 | 2018 | 30274 | 0.04 | Why? |
| Intracranial Arteriovenous Malformations | 1 | 2017 | 71 | 0.04 | Why? |
| Genetic Association Studies | 1 | 2021 | 559 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| Injections, Intra-Articular | 1 | 2017 | 104 | 0.04 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.04 | Why? |
| Kidney Transplantation | 1 | 2017 | 5397 | 0.04 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.04 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.04 | Why? |
| Child | 4 | 2020 | 70012 | 0.04 | Why? |
| Coinfection | 2 | 2017 | 6820 | 0.04 | Why? |
| Intraoperative Care | 1 | 2018 | 238 | 0.04 | Why? |
| Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 234 | 0.04 | Why? |
| Forkhead Transcription Factors | 1 | 2017 | 231 | 0.04 | Why? |
| Liver Transplantation | 1 | 2012 | 2864 | 0.04 | Why? |
| CD4 Antigens | 1 | 2017 | 306 | 0.04 | Why? |
| Gene Frequency | 1 | 2021 | 1210 | 0.04 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| Valine | 1 | 2017 | 359 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Confidence Intervals | 1 | 2017 | 744 | 0.04 | Why? |
| Tears | 1 | 2018 | 400 | 0.03 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.03 | Why? |
| Alanine Transaminase | 1 | 2020 | 1329 | 0.03 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.03 | Why? |
| Bone Density | 1 | 2017 | 335 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Cornea | 1 | 2018 | 410 | 0.03 | Why? |
| Allografts | 1 | 2017 | 761 | 0.03 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.03 | Why? |
| Adrenergic beta-Antagonists | 1 | 2017 | 465 | 0.03 | Why? |
| Carbamates | 1 | 2017 | 485 | 0.03 | Why? |
| Single-Blind Method | 1 | 2017 | 1283 | 0.03 | Why? |
| Pyrrolidines | 1 | 2017 | 558 | 0.03 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2021 | 861 | 0.03 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2020 | 1648 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2017 | 1115 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.03 | Why? |
| Postoperative Care | 1 | 2018 | 755 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.03 | Why? |
| Biological Specimen Banks | 1 | 2020 | 1142 | 0.03 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Intensive Care Units, Neonatal | 1 | 2018 | 749 | 0.03 | Why? |
| Texas | 1 | 2017 | 1237 | 0.03 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.03 | Why? |
| Imidazoles | 1 | 2017 | 631 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.03 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.03 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.03 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.02 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Risk | 1 | 2021 | 5288 | 0.02 | Why? |
| Ventricular Function, Left | 1 | 2017 | 1555 | 0.02 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2020 | 3088 | 0.02 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.02 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.02 | Why? |
| Hospital Mortality | 2 | 2020 | 22087 | 0.02 | Why? |
| Liver | 1 | 2020 | 4007 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.02 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.02 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.01 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Protease Inhibitors | 1 | 2017 | 3630 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Registries | 1 | 2020 | 12327 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 5277 | 0.01 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.01 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2018 | 27595 | 0.01 | Why? |